2013
A planned, prospective comparison of short-term quality of life outcomes among older patients with breast cancer treated with standard chemotherapy in a randomized clinical trial vs. an observational study: CALGB #49907 and #369901
Mandelblatt JS, Makgoeng SB, Luta G, Hurria A, Kimmick G, Isaacs C, Tallarico M, Barry WT, Pitcher B, Winer EP, Hudis C, Cohen HJ, Muss HB. A planned, prospective comparison of short-term quality of life outcomes among older patients with breast cancer treated with standard chemotherapy in a randomized clinical trial vs. an observational study: CALGB #49907 and #369901. Journal Of Geriatric Oncology 2013, 4: 353-361. PMID: 24472479, PMCID: PMC3910230, DOI: 10.1016/j.jgo.2013.05.004.Peer-Reviewed Original ResearchConceptsRandomized clinical trialsOlder womenStandard chemotherapyClinical trialsProspective comparisonObservational studyBreast cancerNon-metastatic breast cancerOlder cancer populationPre-treatment QoLTherapy side effectsBreast cancer chemotherapyShort-term qualityAdjusted mean increaseQuality of lifeTumor factorsOlder patientsAnthracycline regimensQOL scoresGlobal QoLCancer populationSide effectsGroup physiciansChemotherapyLinear mixed effects models
2011
Risk of myocardial infarction, stroke, and fracture in a cohort of community-based breast cancer patients
Ligibel JA, James O’Malley A, Fisher M, Daniel GW, Winer EP, Keating NL. Risk of myocardial infarction, stroke, and fracture in a cohort of community-based breast cancer patients. Breast Cancer Research And Treatment 2011, 131: 589-597. PMID: 21881937, DOI: 10.1007/s10549-011-1754-1.Peer-Reviewed Original ResearchConceptsAdjuvant aromatase inhibitorsBreast cancer patientsCommunity-based populationCancer patientsSerious side effectsMyocardial infarctionHormonal therapyClinical trialsSide effectsOnly serious side effectTime-varying treatment variablesHealthCore Integrated Research DatabaseCox proportional hazards modelNon-trial populationSide effect profileRisk of osteoporosisProportional hazards modelHip fractureEffect profileDiagnosis codesAromatase inhibitorsHigh riskPropensity score methodsLower riskHazards model
2009
Use of BIBW 2992, a novel irreversible EGFR/HER2 tyrosine kinase inhibitor (TKI), to treat patients with HER2-positive metastatic breast cancer after failure of treatment with trastuzumab
Hickish T, Wheatley D, Lin N, Carey L, Houston S, Mendelson D, Solca F, Uttenreuther-Fischer M, Jones H, Winer E. Use of BIBW 2992, a novel irreversible EGFR/HER2 tyrosine kinase inhibitor (TKI), to treat patients with HER2-positive metastatic breast cancer after failure of treatment with trastuzumab. Journal Of Clinical Oncology 2009, 27: 1023-1023. DOI: 10.1200/jco.2009.27.15_suppl.1023.Peer-Reviewed Original ResearchHER2-positive metastatic breast cancerPhase II studyMetastatic breast cancerBIBW 2992Tyrosine kinase inhibitorsPartial responseBreast cancerEpidermal growth factor receptorStable diseaseAdverse eventsII studyDisease progressionTumor assessmentOpen-label single-arm phase II studySide effectsEastern Cooperative Oncology Group performance statusSingle-arm phase II studyHER2-positive breast cancer patientsDual epidermal growth factor receptorArm phase II studyTrastuzumab-resistant cell linesEGFR/HER2 tyrosine kinase inhibitorHER2-positive breast cancerHER2 tyrosine kinase inhibitorAdequate organ functionPaclitaxel in older women with breast cancer. Combined analysis of CALGB 9342 and 9840 with a focus on age.
Lichtman S, Hurria A, Cirrincione C, Seidman A, Winer E, Hudis C, Cohen H, Muss H. Paclitaxel in older women with breast cancer. Combined analysis of CALGB 9342 and 9840 with a focus on age. Cancer Research 2009, 69: 6112. DOI: 10.1158/0008-5472.sabcs-6112.Peer-Reviewed Original ResearchFirst-line therapyLines of therapyBreast cancerPatient ageOlder womenSide effectsLine therapyOlder adultsIncidence of gradeOnset of gradePrior chemotherapy regimenSecond-line patientsSingle-agent paclitaxelDoses of paclitaxelMetastatic breast cancerOnset of neurotoxicityRisk of fallsStandard prognostic variablesAge categoriesLikelihood of responseBetter performance scoresPerformance scoresBilirubin elevationPaclitaxel efficacyWeekly paclitaxel
2008
VEGF as a Marker for Outcome Among Advanced Breast Cancer Patients Receiving anti-VEGF Therapy with Bevacizumab and Vinorelbine Chemotherapy
Burstein HJ, Chen YH, Parker LM, Savoie J, Younger J, Kuter I, Ryan PD, Garber JE, Chen H, Campos SM, Shulman LN, Harris LN, Gelman R, Winer EP. VEGF as a Marker for Outcome Among Advanced Breast Cancer Patients Receiving anti-VEGF Therapy with Bevacizumab and Vinorelbine Chemotherapy. Clinical Cancer Research 2008, 14: 7871-7877. PMID: 19047116, DOI: 10.1158/1078-0432.ccr-08-0593.Peer-Reviewed Original ResearchConceptsAdvanced breast cancer patientsRefractory breast cancerBreast cancer patientsBreast cancerPlasma VEGFCancer patientsTreatment outcomesSide effectsAnti-vascular endothelial growth factor therapyAdequate end-organ functionEndothelial growth factor therapyImportant new treatment modalityTumor hormone receptor statusMonoclonal anti-VEGF antibodyPrior chemotherapy regimensEnd-organ functionHormone receptor statusAnti-VEGF therapyMetastatic breast cancerGrowth factor therapyNew treatment modalitiesWarrants further evaluationAnti-VEGF antibodyBaseline VEGFEligible patients
2007
Trastuzumab plus vinorelbine or taxane chemotherapy for HER2‐overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study
Burstein HJ, Keshaviah A, Baron AD, Hart RD, Lambert‐Falls R, Marcom PK, Gelman R, Winer EP. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2‐overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study. Cancer 2007, 110: 965-972. PMID: 17614302, DOI: 10.1002/cncr.22885.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAlopeciaAnemiaAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsConstipationDisease ProgressionDrug Administration ScheduleFatigueFemaleHumansKaplan-Meier EstimateMiddle AgedNauseaNeoplasm MetastasisPaclitaxelProspective StudiesReceptor, ErbB-2TrastuzumabTreatment OutcomeVinblastineVinorelbineConceptsMetastatic breast cancerBreast cancerTrastuzumab armEpisodes of cardiotoxicityFirst-line therapyDermatologic toxicitiesEvaluable patientsPrior chemotherapyVinorelbine therapyAdvanced diseaseChemotherapy regimenEligible patientsGastrointestinal toxicityPoor accrualTaxane chemotherapyTaxane therapyMore anemiaMedian timeTrastuzumab treatmentFluid retentionDisease progressionChemotherapy agentsTreatment decisionsVinorelbineSide effects
2004
Long-Term Complications of Adjuvant Chemotherapy for Early Stage Breast Cancer
Partridge AH, Winer EP. Long-Term Complications of Adjuvant Chemotherapy for Early Stage Breast Cancer. Breast Disease 2004, 21: 55-64. PMID: 15687723, DOI: 10.3233/bd-2004-21108.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCardiovascular DiseasesChemotherapy, AdjuvantCognition DisordersDose-Response Relationship, DrugDrug Administration ScheduleFemaleHumansMastectomy, SegmentalMiddle AgedNeoplasm StagingPeripheral Nervous System DiseasesPrognosisRandomized Controlled Trials as TopicRisk AssessmentSurvival AnalysisTime FactorsTreatment OutcomeConceptsLong-term complicationsEarly-stage breast cancerAdjuvant chemotherapyStage breast cancerBreast cancerSide effectsRare long-term complicationAcute side effectsLong-term riskTerm complicationsSpecific complicationsRisk factorsIncidence rateLong-term effectsChemotherapyComplicationsLate onsetSustained impactCancerReview detailsPotential riskRiskPatientsEtiologyTherapy
2001
Side Effects of Chemotherapy and Combined Chemohormonal Therapy in Women With Early-Stage Breast Cancer
Partridge A, Burstein H, Winer E. Side Effects of Chemotherapy and Combined Chemohormonal Therapy in Women With Early-Stage Breast Cancer. JNCI Monographs 2001, 2001: 135-142. PMID: 11773307, DOI: 10.1093/oxfordjournals.jncimonographs.a003451.Peer-Reviewed Original ResearchConceptsLong-term side effectsSide effectsChemohormonal therapyAdjuvant chemotherapyShort-term side effectsEarly-stage breast cancerSide effect profileDuration of treatmentLong-term toxicityAdjuvant regimenLate complicationsEffect profileTherapy regimensBreast cancerChemotherapySpecific agentsTherapyToxic effectsPossible risksTreatmentPotential benefitsConsiderable variabilityRegimenRegimensComplicationsNew Combinations with Herceptin® in Metastatic Breast Cancer
Winer E, Burstein H. New Combinations with Herceptin® in Metastatic Breast Cancer. Oncology 2001, 61: 50-57. PMID: 11694788, DOI: 10.1159/000055402.Peer-Reviewed Original ResearchMeSH KeywordsAnastrozoleAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicCyclophosphamideDeoxycytidineDoxorubicinDrug InteractionsDrug SynergismEpirubicinFemaleFluorouracilGemcitabineHeart DiseasesHematologic DiseasesHumansMethotrexateNeoplasm MetastasisNitrilesOrganoplatinum CompoundsPaclitaxelTamoxifenThiotepaTrastuzumabTreatment OutcomeTriazolesVinblastineVinorelbineConceptsMetastatic breast cancerBreast cancerHormonal agentsSide effectsHER2-positive metastatic breast cancerPivotal phase III trialsHER2-positive breast cancerSingle-agent vinorelbineCombination of trastuzumabPhase II trialPhase III trialsMajor side effectsPossible side effectsHormonal therapyII trialIII trialsCombination regimensPreclinical dataClinical trialsMost womenBetter outcomesTrastuzumabCancerTrialsLiposomal formulationNew cytotoxic agents and schedules for advanced breast cancer
Burstein H, Bunnell C, Winer E. New cytotoxic agents and schedules for advanced breast cancer. Seminars In Oncology 2001, 28: 344-358. DOI: 10.1053/sonc.2001.26146.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBreast NeoplasmsCisplatinClinical Trials as TopicDeoxycytidineDocetaxelDoxorubicinEnzyme InhibitorsFemaleFluorouracilGemcitabineHumansLiposomesPaclitaxelTaxoidsTopoisomerase I InhibitorsTrastuzumabVinblastineVinorelbineConceptsAdvanced breast cancerBreast cancerSide effectsUse of chemotherapyCombination of chemotherapyNovel biological agentsNew cytotoxic agentsTreatment of womenSuch biological therapiesCytotoxic chemotherapyBiological therapyVariety of agentsClinical activityAvailable agentsBetter survivalChemotherapyOral chemotherapeuticsCancerCytotoxic agentsWomenBiological agentsAgentsTherapyImportant studiesNew cytotoxic agents and schedules for advanced breast cancer
Burstein H, Bunnell C, Winer E. New cytotoxic agents and schedules for advanced breast cancer. Seminars In Oncology 2001, 28: 344-358. PMID: 11498829, DOI: 10.1016/s0093-7754(01)90129-0.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBreast NeoplasmsCisplatinClinical Trials as TopicDeoxycytidineDocetaxelDoxorubicinEnzyme InhibitorsFemaleFluorouracilGemcitabineHumansLiposomesPaclitaxelTaxoidsTopoisomerase I InhibitorsTrastuzumabVinblastineVinorelbineConceptsAdvanced breast cancerBreast cancerSide effectsUse of chemotherapyCombination of chemotherapyNovel biological agentsNew cytotoxic agentsTreatment of womenSuch biological therapiesCytotoxic chemotherapyBiological therapyVariety of agentsClinical activityAvailable agentsBetter survivalChemotherapyOral chemotherapeuticsCancerCytotoxic agentsWomenBiological agentsAgentsTherapyImportant studies
1999
Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older
Vogel C, O’Rourke M, Winer E, Hochster H, Chang A, Adamkiewicz B, White R, McGuirt C. Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older. Annals Of Oncology 1999, 10: 397-402. PMID: 10370781, DOI: 10.1023/a:1008364222793.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAgingAntineoplastic Agents, PhytogenicBreast NeoplasmsDisease-Free SurvivalDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesHumansInfusions, IntravenousMiddle AgedProspective StudiesSeverity of Illness IndexTreatment OutcomeVinblastineVinorelbineConceptsAdvanced breast cancerDose-limiting toxicityBreast cancerSide effectsNonhematologic toxicityElderly patientsMeasurable advanced breast cancerMajor dose-limiting toxicityActivity of vinorelbineMedian dose intensityFirst-line chemotherapyObjective response rateFirst-line therapyPhase II trialSubjective side effectsInjection site reactionsWomen 60 yearsGastrointestinal side effectsGeneralized painIntravenous vinorelbinePrior chemotherapyAbdominal painChest painII trialCytotoxic chemotherapy
1998
Cancer Pain Survey Patient-Centered Issues in Control
Thomason T, McCune J, Bernard S, Winer E, Tremont S, Lindley C. Cancer Pain Survey Patient-Centered Issues in Control. Journal Of Pain And Symptom Management 1998, 15: 275-284. PMID: 9654832, DOI: 10.1016/s0885-3924(98)00016-5.Peer-Reviewed Original ResearchConceptsCancer pain controlPain controlCancer pain managementCancer-related painPain medication useHigher pain intensityCancer patients' perspectivesPain prevalenceCurrent cancer diagnosisMedication usePain intensityPain managementPatients' unwillingnessAmbulatory patientsPain assessmentPatient reluctanceSurvey patientsTreatment recommendationsAnalgesic drugsPatient's perspectiveAssociated dysfunctionEffective treatmentPainSide effectsImpaired function
1997
Reduced rates of metabolism and decreased physical activity in breast cancer patients receiving adjuvant chemotherapy
Demark-Wahnefried W, Hars V, Conaway, Havlin K, Rimer B, McElveen G, Winer E. Reduced rates of metabolism and decreased physical activity in breast cancer patients receiving adjuvant chemotherapy. American Journal Of Clinical Nutrition 1997, 65: 1495-1501. PMID: 9129482, DOI: 10.1093/ajcn/65.5.1495.Peer-Reviewed Original ResearchConceptsBreast cancer patientsAdjuvant chemotherapyCancer patientsPhysical activityEnergy intakeWeight gainBreast cancerBody compositionCompletion of chemotherapyCommon side effectsCourse of therapyDiet-induced thermogenesisQuality of lifePremenopausal patientsLeucovorin chemotherapyChemotherapySide effectsStage IBaseline levelsPatientsImpairs survivalEnergy expenditureOptimal interventionIntakeComplete data
1993
Why women gain weight with adjuvant chemotherapy for breast cancer.
Demark-Wahnefried W, Winer EP, Rimer BK. Why women gain weight with adjuvant chemotherapy for breast cancer. Journal Of Clinical Oncology 1993, 11: 1418-29. PMID: 8315439, DOI: 10.1200/jco.1993.11.7.1418.Peer-Reviewed Original ResearchConceptsAdjuvant chemotherapyBreast cancer patientsWeight gainCancer patientsBreast cancerEarly-stage breast cancerDietary intervention programCommon side effectsQuality of lifeAmount of weightMultiagent regimensPremenopausal womenDietary intakePhysical activityChemotherapySide effectsEnergy imbalanceEffective interventionsAdverse effectsWomenIntervention programsPatientsAdverse consequencesCancerNumber of investigators